EXACT Sciences (EXAS) versus Puma Biotechnology (PBYI) Critical Review
EXACT Sciences (NASDAQ: EXAS) and Puma Biotechnology (NASDAQ:PBYI) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.
This table compares EXACT Sciences and Puma Biotechnology’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares EXACT Sciences and Puma Biotechnology’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|EXACT Sciences||$99.38 million||61.71||-$167.21 million||($1.15)||-44.54|
|Puma Biotechnology||N/A||N/A||-$276.01 million||($8.18)||-12.19|
EXACT Sciences has higher revenue and earnings than Puma Biotechnology. EXACT Sciences is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
82.4% of EXACT Sciences shares are held by institutional investors. Comparatively, 96.1% of Puma Biotechnology shares are held by institutional investors. 4.0% of EXACT Sciences shares are held by insiders. Comparatively, 21.1% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a breakdown of current ratings and recommmendations for EXACT Sciences and Puma Biotechnology, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
EXACT Sciences presently has a consensus price target of $51.46, suggesting a potential upside of 0.47%. Puma Biotechnology has a consensus price target of $130.67, suggesting a potential upside of 31.06%. Given Puma Biotechnology’s stronger consensus rating and higher possible upside, analysts plainly believe Puma Biotechnology is more favorable than EXACT Sciences.
Volatility and Risk
EXACT Sciences has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.
Puma Biotechnology beats EXACT Sciences on 6 of the 11 factors compared between the two stocks.
EXACT Sciences Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.